Patents by Inventor Agnes E. HAMBURGER

Agnes E. HAMBURGER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PACAP antibodies and uses thereof
    Patent number: 11780914
    Abstract: The present invention relates to monoclonal antibodies that specifically bind to human pituitary adenylate cyclase activating polypeptide (PACAP) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the monoclonal antibodies are also described.
    Type: Grant
    Filed: September 24, 2020
    Date of Patent: October 10, 2023
    Inventors: Agnes E. Hamburger, Cen Xu, Hong Sun, Yuan D. Shih, Dohan Weeraratne
  • NUCLEIC ACID ENCODING LILRB1-BASED CHIMERIC ANTIGEN RECEPTOR
    Publication number: 20230029341
    Abstract: Provided are polynucleotides comprising nucleic acid sequences encoding chimeric antigen receptors having the hinge, transmembrane region, and/or intracellular domain of LILRB1, or functional fragments or variants thereof. Also provided herein are vectors and immune cells comprising said polynucleotides.
    Type: Application
    Filed: December 11, 2020
    Publication date: January 26, 2023
    Inventors: Carl Alexander Kamb, Agnes E. Hamburger, Breanna Diandreth, Mark E. Daris, Kiran Deshmukh
  • IMMUNE CELLS EXPRESSING RECEPTOR SPECIFIC TO CLASS I MHC MOLECULE AND INTERFERING RNA FOR HLA GENE
    Publication number: 20220370498
    Abstract: The disclosure relates to immune cells for use in adoptive cell therapy that express an inhibitory receptor, useful for treating a disease or disorder, for example, cancer. The disclosure provides immune cells with reduced or eliminated HLA expression, that express an inhibitory receptor, methods of making same, shRNAs targeting HLA-A mRNA, and polynucleotides and vectors encoding same.
    Type: Application
    Filed: April 14, 2022
    Publication date: November 24, 2022
    Inventors: Agnes E. HAMBURGER, Carl Alexander KAMB, Breanna DIANDRETH
  • IMMUNE CELLS EXPRESSING RECEPTOR SPECIFIC TO CLASS I MHC MOLECULE AND INTERFERING RNA FOR BETA2 MICROGLOBULIN GENE
    Publication number: 20220315931
    Abstract: The disclosure relates to immune cells for use in adoptive cell therapy useful for treating a disease or disorder, for example, cancer. The disclosure provides immune cells with reduced or eliminated B2M expression, that express an inhibitory receptor, methods of making same, shRNAs targeting B2M mRNA, and polynucleotides and vectors encoding same.
    Type: Application
    Filed: March 28, 2022
    Publication date: October 6, 2022
    Inventors: Agnes E. HAMBURGER, Carl Alexander KAMB, Breanna DIANDRETH
  • LILRB1-BASED CHIMERIC ANTIGEN RECEPTOR
    Publication number: 20220289818
    Abstract: Provided are chimeric antigen receptors having the hinge, transmembrane region, and/or intracellular domain of LILRB1, or functional fragments or variants thereof. Also provided herein are cells comprising the LILRB1 based receptors, and methods of making and using same.
    Type: Application
    Filed: May 12, 2022
    Publication date: September 15, 2022
    Inventors: Carl Alexander Kamb, Agnes E. Hamburger, Breanna Diandreth, Mark E. Daris, Kiran Deshmukh
  • LILRB1-BASED CHIMERIC ANTIGEN RECEPTOR
    Publication number: 20220162287
    Abstract: Provided are chimeric antigen receptors having the hinge, transmembrane region, and/or intracellular domain of LILRB1, or functional fragments or variants thereof. Also provided herein are cells comprising the LILRB1 based receptors, and methods of making and using same.
    Type: Application
    Filed: January 31, 2022
    Publication date: May 26, 2022
    Inventors: Carl Alexander KAMB, Agnes E. HAMBURGER, Breanna DIANDRETH, Mark E. DARIS, Kiran DESHMUKH
  • LILRB1-BASED CHIMERIC ANTIGEN RECEPTOR
    Publication number: 20220153807
    Abstract: Provided are chimeric antigen receptors having the hinge, transmembrane region, and/or intracellular domain of LILRB1, or functional fragments or variants thereof. Also provided herein are cells comprising the LILRB1 based receptors, and methods of making and using same.
    Type: Application
    Filed: January 31, 2022
    Publication date: May 19, 2022
    Inventors: Carl Alexander KAMB, Agnes E. HAMBURGER, Breanna DIANDRETH, Mark E. DARIS, Kiran DESHMUKH
  • LILRB1-based chimeric antigen receptor
    Patent number: 11254726
    Abstract: Provided are chimeric antigen receptors having the hinge, transmembrane region, and/or intracellular domain of LILRB1, or functional fragments or variants thereof. Also provided herein are cells comprising the LILRB1 based receptors, and methods of making and using same.
    Type: Grant
    Filed: April 14, 2021
    Date of Patent: February 22, 2022
    Assignee: A2 Biotherapeutics, Inc.
    Inventors: Carl Alexander Kamb, Agnes E. Hamburger, Breanna Diandreth, Mark E. Daris, Kiran Deshmukh
  • LILRB1-BASED CHIMERIC ANTIGEN RECEPTOR
    Publication number: 20210230247
    Abstract: Provided are chimeric antigen receptors having the hinge, transmembrane region, and/or intracellular domain of LILRB1, or functional fragments or variants thereof. Also provided herein are cells comprising the LILRB1 based receptors, and methods of making and using same.
    Type: Application
    Filed: April 14, 2021
    Publication date: July 29, 2021
    Inventors: Carl Alexander KAMB, Agnes E. HAMBURGER, Breanna DIANDRETH, Mark E. DARIS, Kiran DESHMUKH
  • PACAP ANTIBODIES AND USES THEREOF
    Publication number: 20210095016
    Abstract: The present invention relates to monoclonal antibodies that specifically bind to human pituitary adenylate cyclase activating polypeptide (PACAP) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the monoclonal antibodies are also described.
    Type: Application
    Filed: September 24, 2020
    Publication date: April 1, 2021
    Applicant: AMGEN INC.
    Inventors: Agnes E. HAMBURGER, Cen XU, Hong SUN, Yuan D. SHIH, Dohan WEERARATNE
  • PACAP antibodies and uses thereof
    Patent number: 10822408
    Abstract: The present invention relates to monoclonal antibodies that specifically bind to human pituitary adenylate cyclase activating polypeptide (PACAP) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the monoclonal antibodies are also described.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: November 3, 2020
    Assignee: AMGEN INC.
    Inventors: Agnes E. Hamburger, Cen Xu, Hong Sun, Yuan D. Shih, Dohan Weeraratne
  • PACAP ANTIBODIES AND USES THEREOF
    Publication number: 20180362643
    Abstract: The present invention relates to monoclonal antibodies that specifically bind to human pituitary adenylate cyclase activating polypeptide (PACAP) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the monoclonal antibodies are also described.
    Type: Application
    Filed: December 15, 2016
    Publication date: December 20, 2018
    Applicant: AMGEN INC.
    Inventors: Agnes E. HAMBURGER, Cen XU, Hong SUN, Yuan D. SHIH, Dohan WEERARATNE